Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Lenvatinib in Second Line Endometrial Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
- Status
- COMPLETED
- Phase
- PHASE2
A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China
- Status
- COMPLETED
- Phase
- PHASE3
Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)
- Status
- COMPLETED
- Phase
- PHASE1
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE1
The Drug Rediscovery Protocol (DRUP Trial)
- Status
- RECRUITING
- Phase
- PHASE2
A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
- Status
- COMPLETED
- Phase
- PHASE2
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE1
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14
- Status
- COMPLETED
- Phase
- PHASE2
Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling
- Status
- WITHDRAWN
- Phase
- PHASE2
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)
- Status
- COMPLETED
- Phase
- PHASE1
A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
- Status
- COMPLETED
- Phase
- PHASE2